<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-57376" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Thyroid Lymphoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kesireddy</surname>
            <given-names>Meghana</given-names>
          </name>
          <aff>University of Texas Medical Branch</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lasrado</surname>
            <given-names>Savita</given-names>
          </name>
          <aff>Father Muller Medical College, Mangalore, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Meghana Kesireddy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Savita Lasrado declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-57376.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Thyroid lymphoma is classified as either primary thyroid lymphoma or secondary thyroid lymphoma. Primary thyroid lymphoma affects the thyroid gland first, then spreads to the lymph nodes and other organs later. Secondary thyroid lymphoma affects lymph nodes and other organs first, then spreads to the thyroid later. Primary thyroid lymphomas are rare and further classified based on the underlying lymphoma subtype. These lymphomas are very sensitive to chemotherapy and radiation, which makes timely diagnosis a very crucial step. Timely diagnosis would enable instituting the appropriate local and systemic therapy early on with good outcomes. This activity reviews the etiology, presentation, evaluation, and management of primary thyroid lymphoma and the role of the interprofessional team in evaluating, diagnosing, and managing the condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between thyroid lymphoma and other thyroid cancers, ensuring accurate diagnosis and appropriate management.</p></list-item><list-item><p>Implement&#x000a0;evidence-based strategies to implement timely and comprehensive evaluations once symptoms indicative of thyroid lymphoma are identified.</p></list-item><list-item><p>Apply knowledge of optimal treatment approaches, including chemoimmunotherapy, chemotherapy, or radiation therapy, based on the specific subtype and stage of thyroid lymphoma.</p></list-item><list-item><p>Collaborate among healthcare professionals, ensuring the involvement of a multidisciplinary team for comprehensive diagnosis and management.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=57376&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=57376">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-57376.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Thyroid lymphoma is classified as either primary thyroid lymphoma or secondary thyroid lymphoma.<xref ref-type="bibr" rid="article-57376.r1">[1]</xref> Primary thyroid lymphoma&#x000a0;initially impacts&#x000a0;the thyroid gland,&#x000a0;with subsequent&#x000a0;spread to the lymph nodes and other organs occurring later. In contrast, secondary thyroid lymphoma&#x000a0;involves&#x000a0;lymph nodes and other organs first, followed by subsequent spread to the thyroid. This&#x000a0;activity exclusively concentrates&#x000a0;on primary thyroid lymphomas.</p>
      </sec>
      <sec id="article-57376.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Primary thyroid lymphoma is uncommon, comprising less than&#x000a0;5% of all thyroid malignancies and less than 3% of all extranodal lymphomas.<xref ref-type="bibr" rid="article-57376.r2">[2]</xref> Primary thyroid lymphoma often&#x000a0;manifests&#x000a0;in individuals with preexisting Hashimoto (chronic autoimmune) thyroiditis, showing a significant&#x000a0;correlation with&#x000a0;previous autoimmune conditions.<xref ref-type="bibr" rid="article-57376.r3">[3]</xref> The risk of developing primary thyroid lymphoma is&#x000a0;nearly 60 times higher in&#x000a0;individuals with thyroiditis compared to those without, typically&#x000a0;emerging 20 to 30 years after the initial diagnosis of thyroiditis.<xref ref-type="bibr" rid="article-57376.r4">[4]</xref></p>
      </sec>
      <sec id="article-57376.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The&#x000a0;yearly estimated incidence of thyroid lymphoma is&#x000a0;approximately 2 per 1 million individuals.<xref ref-type="bibr" rid="article-57376.r5">[5]</xref>&#x000a0;The occurrence and prevalence of primary thyroid lymphoma&#x000a0;are&#x000a0;elevated in&#x000a0;regions with higher rates of thyroiditis.<xref ref-type="bibr" rid="article-57376.r6">[6]</xref>&#x000a0;This condition is more common in females, with a female-to-male predisposition ratio of approximately 4:1. The average diagnosis is around age 65.<xref ref-type="bibr" rid="article-57376.r7">[7]</xref></p>
      </sec>
      <sec id="article-57376.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The chronic antigen stimulation and heightened proliferation of lymphocytes in autoimmune conditions like Hashimoto thyroiditis have been&#x000a0;suggested as&#x000a0;potential contributors to the&#x000a0;malignant transformation&#x000a0;leading to primary thyroid lymphoma.<xref ref-type="bibr" rid="article-57376.r5">[5]</xref>&#x000a0;Notably, there is no discernible association between&#x000a0;conditions like Grave disease, colloid goiter, exposure to ionizing radiation, or chromosomal abnormalities and the development of primary thyroid lymphoma.<xref ref-type="bibr" rid="article-57376.r8">[8]</xref></p>
      </sec>
      <sec id="article-57376.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Almost&#x000a0;all&#x000a0;instances&#x000a0;(98%) of primary thyroid lymphoma&#x000a0;belong to the category of B-cell, non-Hodgkin lymphomas.<xref ref-type="bibr" rid="article-57376.r7">[7]</xref>&#x000a0;Among B-cell lymphomas, the most&#x000a0;prevalent subtype is diffuse large B-cell lymphoma (DLBCL),&#x000a0;encompassing&#x000a0;approximately 60% to 70% of cases. Mucosa-associated lymphoid tissue (MALT) lymphoma/extranodal marginal zone lymphoma follows, constituting 10% to 23% of cases. Follicular lymphoma represents 10% of cases, followed by small lymphocytic lymphoma and chronic lymphocytic lymphoma at&#x000a0;around 3%. Mantle cell lymphoma constitutes less than 1% of cases.</p>
        <p>Other rare histological types include Hodgkin lymphoma (2% of cases), T-cell lymphomas, and lymphoblastic lymphomas (&#x0003c;1% of cases).<xref ref-type="bibr" rid="article-57376.r5">[5]</xref><xref ref-type="bibr" rid="article-57376.r9">[9]</xref>&#x000a0;Intermittent T-cell primary thyroid lymphoma cases have been reported in regions endemic to human T-lymphotropic virus (HTLV) associated adult T-cell leukemia and lymphoma.<xref ref-type="bibr" rid="article-57376.r10">[10]</xref>&#x000a0;If untreated, indolent histologies like MALT lymphoma and extranodal marginal zone lymphoma can transform into aggressive histologies like DLBCL. Mixed histology, ie, DLBCL and MALT occurring together,&#x000a0;is observed in some cases.<xref ref-type="bibr" rid="article-57376.r5">[5]</xref></p>
      </sec>
      <sec id="article-57376.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The aggressiveness of clinical presentation depends on histology, with DLBCL&#x000a0;displaying a more aggressive behavior than indolent lymphomas like MALT lymphoma or follicular lymphomas. The duration of symptoms before diagnosis can range&#x000a0;widely, ranging from a few days to a few years, with a&#x000a0;notably shorter duration reported in DLBCL.<xref ref-type="bibr" rid="article-57376.r11">[11]</xref></p>
        <p>The predominant local symptom is a rapidly enlarging thyroid gland (goiter), accompanied by obstructive symptoms&#x000a0;resulting from the&#x000a0;enlarged gland.<xref ref-type="bibr" rid="article-57376.r7">[7]</xref><xref ref-type="bibr" rid="article-57376.r12">[12]</xref>&#x000a0;These obstructive symptoms include dyspnea, stridor due to tracheal compression, dysphagia due to esophageal compression, neck pain, facial edema due to compression of neck veins and the superior vena cava, and hoarseness of voice due to recurrent laryngeal nerve compression.</p>
        <p>The systemic symptoms&#x000a0;encompass B-symptoms of lymphoma, such as fever, night sweats, and weight loss, as well as symptoms of hypothyroidism, including fatigue, cold intolerance, constipation, dry skin/hair, hoarse voice, and menstrual irregularities. Hypothyroidism in these patients is commonly due to Hashimoto thyroiditis and, infrequently, to diffuse thyroid gland infiltration by the lymphoma. Rarely, some patients may&#x000a0;exhibit symptoms of hyperthyroidism due to the destruction of the thyroid follicles by the lymphoma.<xref ref-type="bibr" rid="article-57376.r13">[13]</xref>&#x000a0;Patients&#x000a0;with Hashimoto thyroiditis&#x000a0;undergoing&#x000a0;thyroid hormone replacement are expected to&#x000a0;maintain&#x000a0;euthyroid status.</p>
        <p>Physical examination&#x000a0;typically reveals a firm to hard, diffusely enlarged, and immobile thyroid gland, accompanied by cervical or supraclavicular lymphadenopathy.<xref ref-type="bibr" rid="article-57376.r12">[12]</xref> Rarely, some patients may&#x000a0;present with a large&#x000a0;distinct nodule instead of diffuse thyroid enlargement.</p>
      </sec>
      <sec id="article-57376.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The workup for thyroid lymphoma should encompass the following:</p>
        <p>
<bold>Laboratory Evaluation</bold>
</p>
        <p>There is no specific or pathognomic laboratory finding in thyroid lymphomas. Laboratory findings&#x000a0;associated with hypothyroidism (elevated thyroid stimulating hormone [TSH], low T3, and T4) and Hashimoto thyroiditis (elevated antithyroglobulin or antithyroid peroxidase antibodies)&#x000a0;are common.<xref ref-type="bibr" rid="article-57376.r14">[14]</xref>&#x000a0;Rarely, laboratory findings&#x000a0;indicate hyperthyroidism, characterized by low TSH and elevated T3 and T4 levels. If patients with Hashimoto thyroiditis are undergoing&#x000a0;thyroid hormone replacement, laboratory findings of euthyroidism (normal TSH, T3, and T4) are expected.&#x000a0;</p>
        <p>
<bold>Imaging</bold>
</p>
        <p>Thyroid ultrasound is the recommended initial imaging modality. Although there are no specific findings, characteristic features&#x000a0;within&#x000a0;1 of the&#x000a0;3 patterns (nodular, diffuse, or mixed) of thyroid appearance can suggest primary thyroid lymphoma. Thyroid ultrasound often&#x000a0;reveals&#x000a0;enhanced posterior echoes, multiple hypoechogenic areas resembling pseudocysts, and increased vascularity.<xref ref-type="bibr" rid="article-57376.r5">[5]</xref><xref ref-type="bibr" rid="article-57376.r15">[15]</xref>&#x000a0;In a prospective study, 74 of 165 patients (47.9%) suspected of having malignant thyroid lymphoma based on ultrasound findings had pathologically confirmed lymphoma.<xref ref-type="bibr" rid="article-57376.r16">[16]</xref></p>
        <p>To determine the extent of disease,&#x000a0;including extrathyroidal spread, tracheal invasion, and lymph node involvement, computed tomography (CT) or magnetic resonance imaging (MRI) are more useful than ultrasound. Other imaging studies like 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) show increased uptake throughout the thyroid gland. PET scans&#x000a0;offer superior diagnostic accuracy in lymphoma for staging and assessing response to treatment but&#x000a0;are&#x000a0;less useful for the initial diagnosis as they cannot differentiate thyroid lymphoma from other conditions like Hashimoto thyroiditis.<xref ref-type="bibr" rid="article-57376.r17">[17]</xref></p>
        <p>
<bold>Pathology</bold>
</p>
        <p>The definitive diagnosis of primary thyroid lymphoma is&#x000a0;established through histopathological analysis of tissue. Fine needle aspiration (FNA) is the initial diagnostic procedure for thyroid tissue sampling.<xref ref-type="bibr" rid="article-57376.r2">[2]</xref><xref ref-type="bibr" rid="article-57376.r15">[15]</xref> FNA alone has low sensitivity,&#x000a0;diagnosing only 50% to 80% of cases depending on the study, and is more likely to be diagnostic in patients with a large lymphoma burden.<xref ref-type="bibr" rid="article-57376.r2">[2]</xref><xref ref-type="bibr" rid="article-57376.r18">[18]</xref>&#x000a0;Core biopsy is more sensitive than FNA, providing larger tissue samples and preserving tissue architecture, facilitating the differentiation between thyroiditis and lymphoma, and identifying the lymphoma subtype.&#x000a0;Although the sensitivity of FNA has improved with newer adjuncts like flow cytometry and immunohistochemical staining that help establish the monoclonality of lymphocytes, a core biopsy is still suggested for definitive diagnosis when primary thyroid lymphoma is suspected.<xref ref-type="bibr" rid="article-57376.r15">[15]</xref><xref ref-type="bibr" rid="article-57376.r19">[19]</xref>&#x000a0;Open surgical biopsy is&#x000a0;reserved for cases where less invasive techniques (like FNA or core needle biopsy)&#x000a0;cannot definitively establish the diagnosis or identify the&#x000a0;subtype of primary thyroid lymphoma.<xref ref-type="bibr" rid="article-57376.r2">[2]</xref></p>
      </sec>
      <sec id="article-57376.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management&#x000a0;of primary thyroid lymphoma depends on the histological subtype and staging of the tumor.&#x000a0;Given&#x000a0;the rarity of primary thyroid lymphoma, large prospective randomized trials for optimal management are limited. Treatment recommendations primarily derive&#x000a0;from extrapolation based on&#x000a0;prospective, randomized studies in non-Hodgkin lymphomas.&#x000a0;</p>
        <p>For DLBCL histology, combined modality treatment&#x000a0;involving chemotherapy and radiotherapy is preferred for limited-stage (IE or IIE) DLBCL, as it is associated with a higher 5-year failure-free survival rate than chemotherapy alone.<xref ref-type="bibr" rid="article-57376.r20">[20]</xref>&#x000a0;For advanced stage (IIIE or IV) DLBCL, the first-line treatment involves rituximab (a monoclonal antibody selectively binding the&#x000a0;CD20 antigen on the pre-B and mature B lymphocytes) in combination with chemotherapy (R-CHOP:&#x000a0;rituximab in combination with cyclophosphamide, doxorubicin, vincristine, prednisolone).&#x000a0;</p>
        <p>For other histologies like MALT lymphoma and follicular lymphoma, treatment options for limited-stage (IE or IIE) include radiotherapy alone or combined modality treatment with&#x000a0;chemoimmunotherapy using rituximab. For advanced-stage (IIIE or IV) indolent varieties of thyroid lymphoma, rituximab alone or in combination with chemotherapy stands as the first-line treatment option.<xref ref-type="bibr" rid="article-57376.r20">[20]</xref><xref ref-type="bibr" rid="article-57376.r21">[21]</xref></p>
        <p>Surgery is generally not recommended for the treatment of primary thyroid lymphoma. It holds no role&#x000a0;beyond diagnostic biopsy due to potential surgical risks and&#x000a0;the absence of additional benefits compared to chemoradiation therapy.<xref ref-type="bibr" rid="article-57376.r2">[2]</xref>&#x000a0;Obstructive symptoms usually improve within days of chemotherapy (R-CHOP) initiation due to the steroid in the regimen.&#x000a0;The rapid alleviation of symptoms allows for the&#x000a0;safe and successful medical management of severe airway compromise due to tracheal compression, often avoiding the need for tracheostomy or thyroidectomy.<xref ref-type="bibr" rid="article-57376.r2">[2]</xref></p>
        <p>The management strategy for hypothyroidism symptoms, whether arising from Hashimoto thyroiditis, diffuse thyroid gland infiltration by the lymphoma, or radiation-associated hypothyroidism, involves thyroid hormone replacement. A study at the Mayo Clinic demonstrated that diagnostic biopsy followed by definitive chemotherapy alone was more effective in complete remission rates than undergoing surgical debulking followed by adjuvant therapies.<xref ref-type="bibr" rid="article-57376.r22">[22]</xref></p>
        <p>Treatment failures, categorized as refractory lymphoma (no response to initial treatment or reoccurrence shortly after completing treatment) or relapsed lymphoma (responds to treatment and&#x000a0;enters&#x000a0;remission but recurs after a period), can occur. Subsequent treatment options for refractory and relapsed cases&#x000a0;vary, contingent on histology and time taken for relapse following initial treatment. These options are primarily&#x000a0;informed by evidence from&#x000a0;non-Hodgkin lymphoma trials and studies.</p>
      </sec>
      <sec id="article-57376.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The&#x000a0;primary differential diagnosis for primary thyroid lymphoma is anaplastic thyroid carcinoma, given its clinical resemblance characterized by the presentation of a rapidly growing thyroid mass that is firm and fixed to surrounding structures. Other differentials include primary thyroid carcinomas like papillary thyroid carcinoma, follicular thyroid carcinoma, and medullary thyroid carcinoma, and benign conditions like simple colloid goiter and benign thyroid nodules.</p>
        <p>Despite its rarity, primary thyroid lymphoma should always be considered in the list of potential diagnoses for any rapidly growing thyroid nodules or goiter. Early diagnosis and appropriate management&#x000a0;play a crucial role in impacting the prognosis.&#x000a0;</p>
      </sec>
      <sec id="article-57376.s11" sec-type="Staging">
        <title>Staging</title>
        <p>The Lugano staging system or modified Ann Arbor staging classification determines the staging of primary thyroid lymphomas.<xref ref-type="bibr" rid="article-57376.r23">[23]</xref> Imaging for lymphoma staging includes imaging the whole body with either FDG PET/ CT for FDG avid lymphomas or CT&#x000a0;scans (of the head, neck, chest, abdomen, and pelvis)&#x000a0;for FDG non-avid lymphomas like MALT lymphoma and small lymphocytic lymphoma. Almost 80% of patients&#x000a0;present with limited disease (stage IE: thyroid only or IIE: thyroid with regional lymph nodes involvement), while about 20% of patients have advanced disease (stage IIIE: thyroid with lymph nodes and organs involvement on both sides of the diaphragm or stage IV: disseminated lymphoma).<xref ref-type="bibr" rid="article-57376.r7">[7]</xref><xref ref-type="bibr" rid="article-57376.r24">[24]</xref>&#x000a0;Accurate staging at the time of presentation is crucial for assessing prognosis, determining the appropriate treatment, and evaluating treatment response.</p>
      </sec>
      <sec id="article-57376.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of primary thyroid lymphoma depends on various factors such as histology, tumor burden, stage, age, performance status, treatment modality, and type.&#x000a0;Histology-specific disease-free survival rates from the Surveillance Epidemiology and End Result (SEER) database estimate a 5-year disease-free survival rate of 96% for MALT lymphoma, 87% for follicular lymphoma, 86% for small lymphocytic lymphoma, and 75% for DLBCL.<xref ref-type="bibr" rid="article-57376.r2">[2]</xref>&#x000a0;Histology-specific overall survival rates from the UK lymphoma treatment center experience estimate a 5-year survival rate of 75% for indolent B-cell lymphoma not otherwise specified, 62% for MALT lymphoma, and 45% for DLBCL, with a median overall survival of all histological subtypes&#x000a0;being 5.7 years.<xref ref-type="bibr" rid="article-57376.r25">[25]</xref></p>
      </sec>
      <sec id="article-57376.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications&#x000a0;arising from&#x000a0;thyroid lymphoma include life-threatening&#x000a0;issues like airway compromise due to tracheal compression, superior vena cava syndrome due to superior vena cava compression, and dysphagia due to esophageal compression. Additionally, complications&#x000a0;stemming&#x000a0;from lymphoma treatment include radiation-associated hypothyroidism, radiation-associated malignancies of the thyroid or other exposed organs, chemotherapy-related side effects like peripheral neuropathy due to vincristine, congestive heart failure due to doxorubicin, conditions such as hemorrhagic cystitis or bladder cancer due to cyclophosphamide.</p>
      </sec>
      <sec id="article-57376.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Lymphoma is characterized by the uncontrolled growth of&#x000a0;cohesive cancerous lymphatic cells. In thyroid lymphoma, these&#x000a0;aberrant lymphoid cells&#x000a0;cause the&#x000a0;thyroid&#x000a0;gland&#x000a0;to enlarge, leading to various symptoms associated with thyroid dysfunction and gland enlargement. Patients may also experience symptoms like fever, night sweats, and weight loss due to the lymphoma itself. Multiple laboratory investigations, imaging, and thyroid gland biopsy are needed to establish the diagnosis and stage of the lymphoma.</p>
        <p>Treatment options are diverse and depend on the specific subtype and stage of the lymphoma, typically involving a multidisciplinary team of specialists such as medical oncologists, radiation oncologists, oncology pharmacists, and oncology nurses. The prognosis is influenced by factors like age, functional status, tumor type, and stage, but overall, primary thyroid lymphoma&#x000a0;demonstrates an excellent prognosis&#x000a0;when promptly identified and treated.</p>
      </sec>
      <sec id="article-57376.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to&#x000a0;keep in mind about thyroid lymphoma are as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Early recognition of thyroid lymphoma is crucial for optimal outcomes.</p>
          </list-item>
          <list-item>
            <p>Proper staging using the Lugano system guides treatment decisions.</p>
          </list-item>
          <list-item>
            <p>Prognosis varies with factors such as histology, stage, and treatment modality.</p>
          </list-item>
          <list-item>
            <p>A multidisciplinary approach involving medical oncologists, radiation oncologists, and otolaryngologists is essential.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-57376.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of primary thyroid lymphoma&#x000a0;necessitates&#x000a0;the involvement of an interprofessional team&#x000a0;comprising specialists from different departments, including a medical oncologist, radiation oncologist, otolaryngologist, primary care physician, endocrinologist, pathologist, and specialty care nurses. Typically, patients present to their primary care physician,&#x000a0;nurse practitioner, or endocrinologist with an enlarged neck mass and obstructive symptoms. The initial physician must maintain a high&#x000a0;level of suspicion for thyroid lymphoma and&#x000a0;collaborate with&#x000a0;the otolaryngologist and pathologist&#x000a0;to&#x000a0;establish a diagnosis&#x000a0;through a core biopsy of the thyroid.</p>
        <p>Once the diagnosis is confirmed, the medical oncologist, radiation oncologist, and endocrinologist should all be actively involved, and additional workup and treatment should commence immediately. Primary thyroid lymphoma&#x000a0;demonstrates a good prognosis if the patient promptly receives well-coordinated care from all the specialists. Diagnosing and managing&#x000a0;thyroid lymphoma require an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists collaborating across disciplines to achieve optimal patient outcomes. Oncology nurses&#x000a0;play a vital role in administering chemotherapy, educating patients and their families, and&#x000a0;providing the team updates on the patient's status. Pharmacists&#x000a0;contribute by reviewing&#x000a0;medications for dose and drug-drug interactions and participating in education.&#x000a0;</p>
      </sec>
      <sec id="article-57376.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=57376&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=57376">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/thyroid-lymphoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=57376">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/57376/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=57376">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-57376.s18">
        <title>References</title>
        <ref id="article-57376.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Austin</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>el-Naggar</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Goepfert</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Thyroid cancers. II. Medullary, anaplastic, lymphoma, sarcoma, squamous cell.</article-title>
            <source>Otolaryngol Clin North Am</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>611</fpage>
            <page-range>611-27</page-range>
            <pub-id pub-id-type="pmid">8844733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lowery</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Evoy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Prichard</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Thyroid lymphoma: recent advances in diagnosis and optimal management strategies.</article-title>
            <source>Oncologist</source>
            <year>2013</year>
            <volume>18</volume>
            <issue>9</issue>
            <fpage>994</fpage>
            <page-range>994-1003</page-range>
            <pub-id pub-id-type="pmid">23881987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Noh</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mikura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitsumatsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukushita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshihara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Katoh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sugino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Relationship Between Primary Thyroid Lymphoma and Various Types of Thyroid Autoimmunity: A Retrospective Cohort Study of 498 Cases, Including 9 Cases with Graves' Disease.</article-title>
            <source>Thyroid</source>
            <year>2022</year>
            <month>May</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>552</fpage>
            <page-range>552-559</page-range>
            <pub-id pub-id-type="pmid">35229626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hyjek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Isaacson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis.</article-title>
            <source>Hum Pathol</source>
            <year>1988</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>1315</fpage>
            <page-range>1315-26</page-range>
            <pub-id pub-id-type="pmid">3141260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wartofsky</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Primary thyroid lymphoma: a clinical review.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>98</volume>
            <issue>8</issue>
            <fpage>3131</fpage>
            <page-range>3131-8</page-range>
            <pub-id pub-id-type="pmid">23714679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holm</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Blomgren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>L&#x000f6;whagen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cancer risks in patients with chronic lymphocytic thyroiditis.</article-title>
            <source>N Engl J Med</source>
            <year>1985</year>
            <month>Mar</month>
            <day>07</day>
            <volume>312</volume>
            <issue>10</issue>
            <fpage>601</fpage>
            <page-range>601-4</page-range>
            <pub-id pub-id-type="pmid">3838363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pedersen</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>NT</given-names>
              </name>
            </person-group>
            <article-title>Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study.</article-title>
            <source>Histopathology</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-32</page-range>
            <pub-id pub-id-type="pmid">8838117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calandra</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Paloyan</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Total thyroidectomy in irradiated patients. A twenty-year experience in 206 patients.</article-title>
            <source>Ann Surg</source>
            <year>1985</year>
            <month>Sep</month>
            <volume>202</volume>
            <issue>3</issue>
            <fpage>356</fpage>
            <page-range>356-60</page-range>
            <pub-id pub-id-type="pmid">2931054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graff-Baker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Udelsman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases.</article-title>
            <source>Surgery</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>146</volume>
            <issue>6</issue>
            <fpage>1105</fpage>
            <page-range>1105-15</page-range>
            <pub-id pub-id-type="pmid">19958938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohsawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aozasa</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Immunologic type of thyroid lymphoma in an adult T-cell leukemia endemic area in Japan.</article-title>
            <source>Leuk Lymphoma</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>3-4</issue>
            <fpage>341</fpage>
            <page-range>341-4</page-range>
            <pub-id pub-id-type="pmid">8580806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derringer</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Frommelt</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Bijwaard</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Heffess</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Abbondanzo</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2000</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>623</fpage>
            <page-range>623-39</page-range>
            <pub-id pub-id-type="pmid">10800981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skarsgard</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Robins</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>A current analysis of primary lymphoma of the thyroid.</article-title>
            <source>Arch Surg</source>
            <year>1991</year>
            <month>Oct</month>
            <volume>126</volume>
            <issue>10</issue>
            <fpage>1199</fpage>
            <page-range>1199-203; discussion 1203-4</page-range>
            <pub-id pub-id-type="pmid">1929820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennings</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Saberi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Thyroid lymphoma in a patient with hyperthyroidism.</article-title>
            <source>Am J Med</source>
            <year>1984</year>
            <month>Mar</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>551</fpage>
            <page-range>551-2</page-range>
            <pub-id pub-id-type="pmid">6702880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakorafas</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Kokkoris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Farley</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Primary thyroid lymphoma (correction of lympoma): diagnostic and therapeutic dilemmas.</article-title>
            <source>Surg Oncol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>e124</fpage>
            <page-range>e124-9</page-range>
            <pub-id pub-id-type="pmid">20620043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuzuka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Miyauchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Narabayashi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kuma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases.</article-title>
            <source>Thyroid</source>
            <year>1993</year>
            <season>Summer</season>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-9</page-range>
            <pub-id pub-id-type="pmid">8369658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ota</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuzuka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kuma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fukata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kakudo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Amino</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miyauchi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of ultrasonography for diagnosis of malignant lymphoma of the thyroid.</article-title>
            <source>Thyroid</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>983</fpage>
            <page-range>983-7</page-range>
            <pub-id pub-id-type="pmid">17042683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Treglia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Del Ciello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Franco</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Recurrent lymphoma in the thyroid gland detected by fluorine-18-fluorodeoxyglucose PET/CT.</article-title>
            <source>Endocrine</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>242</fpage>
            <page-range>242-3</page-range>
            <pub-id pub-id-type="pmid">22948774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jasim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reading</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Ristow</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Villasboas Bisneto</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Fatourechi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study.</article-title>
            <source>Thyroid</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>1061</fpage>
            <page-range>1061-7</page-range>
            <pub-id pub-id-type="pmid">27256107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavlidis</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Pavlidis</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>A Review of Primary Thyroid Lymphoma: Molecular Factors, Diagnosis and Management.</article-title>
            <source>J Invest Surg</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-142</page-range>
            <pub-id pub-id-type="pmid">29058491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ha</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Shadle</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wilder</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cabanillas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Localized non-Hodgkin lymphoma involving the thyroid gland.</article-title>
            <source>Cancer</source>
            <year>2001</year>
            <month>Feb</month>
            <day>15</day>
            <volume>91</volume>
            <issue>4</issue>
            <fpage>629</fpage>
            <page-range>629-35</page-range>
            <pub-id pub-id-type="pmid">11241227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cheong</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keum</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Patterns of care and treatment outcomes for primary thyroid lymphoma: a single institution study.</article-title>
            <source>Radiat Oncol J</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>177</fpage>
            <page-range>177-84</page-range>
            <pub-id pub-id-type="pmid">24501704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pyke</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Kurtin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>van Heerden</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bergstralh</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kunselman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>ID</given-names>
              </name>
            </person-group>
            <article-title>Non-Hodgkin's lymphoma of the thyroid: is more than biopsy necessary?</article-title>
            <source>World J Surg</source>
            <year>1992</year>
            <season>Jul-Aug</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>604</fpage>
            <page-range>604-9; discussion 609-10</page-range>
            <pub-id pub-id-type="pmid">1413831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Barrington</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lister</surname>
                <given-names>TA</given-names>
              </name>
              <collab>Alliance, Australasian Leukaemia and Lymphoma Group</collab>
              <collab>Eastern Cooperative Oncology Group</collab>
              <collab>European Mantle Cell Lymphoma Consortium</collab>
              <collab>Italian Lymphoma Foundation</collab>
              <collab>European Organisation for Research</collab>
              <collab>Treatment of Cancer/Dutch Hemato-Oncology Group</collab>
              <collab>Grupo Espa&#x000f1;ol de M&#x000e9;dula &#x000d3;sea</collab>
              <collab>German High-Grade Lymphoma Study Group</collab>
              <collab>German Hodgkin's Study Group</collab>
              <collab>Japanese Lymphorra Study Group</collab>
              <collab>Lymphoma Study Association</collab>
              <collab>NCIC Clinical Trials Group</collab>
              <collab>Nordic Lymphoma Study Group</collab>
              <collab>Southwest Oncology Group</collab>
              <collab>United Kingdom National Cancer Research Institute</collab>
            </person-group>
            <article-title>Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>20</day>
            <volume>32</volume>
            <issue>27</issue>
            <fpage>3059</fpage>
            <page-range>3059-68</page-range>
            <pub-id pub-id-type="pmid">25113753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsang</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Gospodarowicz</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Sutcliffe</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Sturgeon</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Panzarella</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Non-Hodgkin's lymphoma of the thyroid gland: prognostic factors and treatment outcome. The Princess Margaret Hospital Lymphoma Group.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>1993</year>
            <month>Oct</month>
            <day>20</day>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>599</fpage>
            <page-range>599-604</page-range>
            <pub-id pub-id-type="pmid">8226154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-57376.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alzouebi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goepel</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Horsman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Primary thyroid lymphoma: the 40 year experience of a UK lymphoma treatment centre.</article-title>
            <source>Int J Oncol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>2075</fpage>
            <page-range>2075-80</page-range>
            <pub-id pub-id-type="pmid">22367111</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
